TNF and metabolic dysfunction-associated steatohepatitis: In mouse models of non-alcoholic fatty liver disease and its inflammatory progression to non-alcoholic steatohepatitis (NASH), treatment with either compound reduced hepatic steatosis, lowered pro-inflammatory cytokine levels (TNF-α, IL-6), and improved insulin sensitivity and glucose tolerance.